| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B49-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56 |
| filingDate |
2016-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb6165d0a476ae27706bd6fa3e873812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64273a90f1093784c5e167be40808a9e |
| publicationDate |
2017-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2017053711-A2 |
| titleOfInvention |
Deuterated cftr potentiators |
| abstract |
This invention relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, wherein each X and each R is defined within. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111479804-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11708331-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2018375186-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019109021-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10738036-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10759721-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10894773-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10196384-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10479766-B2 |
| priorityDate |
2015-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |